The company remains in a pre-revenue phase, reporting zero sales while incurring a $7.5 million operating loss in 2026Q1, exacerbated by $1.1 million in stock-based compensation.
| Sales/Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Revenue Growth % | - | - | - | - | - | - | - | - |
| Cost of Goods Sold | 826K | 1.43M | 2.11M | 1.85M | 0 | 0 | 0 | 0 |
| COGS % of Revenue | - | - | - | - | - | - | - | - |
| Gross Profit | -826K | -1.43M | -2.11M | -1.85M | 0 | 0 | 0 | 0 |
| Gross Margin % | - | - | - | - | - | - | - | - |
| Gross Profit Growth % | - | 32.37% | -13.65% | - | - | - | - | - |
| Operating Expenses | 41.9M | 49.54M | 64.45M | 78.81M | 80.08M | 38.22M | 12.98M | 9.78M |
| OpEx % of Revenue | - | - | - | - | - | - | - | - |
| Selling, General & Admin | 13.5M | 17.37M | 26.4M | 33.09M | 36.18M | 16.16M | 3.19M | 2.3M |
| SG&A % of Revenue | - | - | - | - | - | - | - | - |
| Research & Development | 29.23M | 33.6M | 40.16M | 47.58M | 43.9M | 22.06M | 9.8M | 7.48M |
| R&D % of Revenue | - | - | - | - | - | - | - | - |
| Other Operating Expenses | -826K | -1.43M | -2.11M | -1.85M | 0 | 0 | 0 | 0 |
| Operating Income | -42.72M | -50.97M | -66.56M | -80.67M | -80.08M | -38.22M | -12.98M | -9.78M |
| Operating Margin % | - | - | - | - | - | - | - | - |
| Operating Income Growth % | - | 23.42% | 17.49% | -0.73% | -109.5% | -194.36% | -32.73% | - |
| EBITDA | -41.48M | -49.54M | -64.45M | -78.81M | -78.97M | -37.91M | -12.83M | -9.68M |
| EBITDA Margin % | - | - | - | - | - | - | - | - |
| EBITDA Growth % | 35.42% | 23.13% | 18.23% | 0.2% | -108.32% | -195.5% | -32.53% | - |
| D&A (Non-Cash Add-back) | 1.24M | 1.43M | 2.11M | 1.85M | 1.11M | 316K | 157K | 104K |
| EBIT | -42.28M | -50.97M | -63.22M | -71.05M | 5.36M | -35.12M | -12.98M | -9.78M |
| Net Interest Income | 567K | 973K | 3.29M | 4.4M | 1.24M | -69K | 110K | 469 |
| Interest Income | 567K | 973K | 3.29M | 4.43M | 1.44M | 20K | 113K | 469 |
| Interest Expense | 0 | 0 | 0 | 25K | 200K | 89K | 3K | 0 |
| Other Income/Expense | 606K | 786K | 3.33M | 9.6M | 85.23M | 3.02M | 110K | 469K |
| Pretax Income | -42.12M | -50.18M | -63.22M | -71.07M | 5.16M | -35.21M | -12.88M | -9.31M |
| Pretax Margin % | - | - | - | - | - | - | - | - |
| Income Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Effective Tax Rate % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| Net Income | -42.12M | -50.18M | -63.22M | -71.07M | 5.16M | -35.21M | -12.88M | -9.31M |
| Net Margin % | - | - | - | - | - | - | - | - |
| Net Income Growth % | 31.65% | 20.63% | 11.04% | -1478.15% | 114.65% | -173.45% | -38.23% | - |
| Net Income (Continuing) | -42.12M | -50.18M | -63.22M | -71.07M | 5.16M | -35.21M | -12.88M | -9.31M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -6.29 | -8.45 | -10.72 | -14.60 | 1.21 | -10.92 | -3.76 | -1.70 |
| EPS Growth % | 35.41% | 21.18% | 26.58% | -1306.61% | 111.08% | -190.43% | -121.18% | - |
| EPS (Basic) | - | -8.45 | -10.72 | -14.70 | 1.27 | -10.92 | -3.76 | -1.70 |
| Diluted Shares Outstanding | 6.7M | 5.94M | 5.89M | 4.87M | 4.25M | 3.22M | 3.42M | 5.47M |
| Basic Shares Outstanding | 6.7M | 5.94M | 5.89M | 4.83M | 4.29M | 3.22M | 3.42M | 5.46M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - |
Imminent liquidity insolvency risk
According to the latest income statement data, Vicarious Surgical continues to report zero revenue while maintaining significant R&D expenditures, which reached $5.0 million in 2026Q1, highlighting a persistent reliance on capital-intensive development cycles that have yet to yield any commercial product sales or service income.
The company's cost structure remains dominated by R&D and SG&A, which collectively continue to drive substantial quarterly operating losses. While there has been a recent reduction in absolute R&D spending compared to the $10.9 million peak in 2024Q2, this appears to be a function of capital preservation rather than operational efficiency, suggesting that the company is struggling to balance necessary innovation with a rapidly depleting cash runway.
As reported in financial statements, the company's net income figures are heavily influenced by stock-based compensation, which totaled $1.1 million in 2026Q1, effectively obscuring the underlying cash burn required to sustain the firm's engineering-heavy development model in the absence of any meaningful top-line revenue generation.
Investors should monitor the reliance on equity-based compensation as a primary tool for talent retention, as it dilutes existing shareholders without addressing the core issue of cash-based operational expenses. The volatility in net income, when adjusted for these non-cash charges, suggests that the company's true economic loss remains deeply negative and highly sensitive to the timing of regulatory milestones.
Based on the provided income statement figures, the company exhibits a high degree of operating leverage risk, as the lack of revenue means that every dollar of SG&A and R&D expense directly exacerbates the quarterly operating loss, which stood at $7.5 million for the most recent period.
The absence of gross profit indicates that the company has not yet achieved the scale necessary to leverage its fixed cost base, leaving it entirely exposed to market-wide capital constraints. Without a clear path to commercialization, the current operating structure appears unsustainable, as the company lacks the revenue-generating assets to offset its ongoing research and administrative overhead.
Data from recent filings indicates that the company's cash reserves have dwindled to approximately $2.57 million, a figure that suggests an extremely high probability of insolvency or significant dilutive financing in the near term, given the historical quarterly burn rates observed over the past ten periods.
Short-sellers would likely focus on the widening gap between the company's development timelines and its rapidly diminishing liquidity position. The inability to reach commercialization while cash reserves are at such critical levels warrants further investigation into whether the current business model can survive without a fundamental restructuring or a major capital infusion.
Quick answers to the most common questions about buying RBOT stock.
For fiscal year 2025, Vicarious Surgical Inc. (RBOT) reported total revenue of $0.0M.
Vicarious Surgical Inc. (RBOT) reported a net loss of $50.2M for the fiscal year ending 2025.